ONCOLOGY G RAND ROUNDS...ONCOLOGY G RAND ROUNDS Experimental Oncology Initiative Tuesday, November...
1
“Targeting Clonal Heterogeneity in Treatment- Refractory Glioblastoma with Novel and Empiric Immunotherapies.” Dr. Sheila K. Singh, PhD, MD, FRCS(C), Pediatric Neurosurgeon, McMaster Children's Hospital Professor of Surgery, McMaster University Principal Investigator, Stem Cell and Cancer Research Institute, McMaster University Senior Canada Research Chair in Human Cancer Stem Cell Biology Director, McMaster Surgeon Scientist Program CEO, Empirica Therapeutics Objectives: to understand how intro-tumoral heterogeneity at the genomic and functional levels complicates our ability to find tractable therapeutic targets for patients with recurrent GBM to review the application of new multi-omic profiling technology to the study of GBM modelling of recurrence, toward the definition of new therapeutic targets to review preclinical validation required to develop therapies for GBM patients against novel biological targets THANK YOU TO OUR SPONSORS: REFRESHMENTS WILL BE PROVIDED BY: Department of Oncology, Schulich School of Medicine & Dentistry London Regional Cancer Program ONCOLOGY GRAND ROUNDS Experimental Oncology Initiative Tuesday, November 19th, 2019 12:00pm to 1:00pm in Rooms A3-924A/B London Regional Cancer Program
Transcript of ONCOLOGY G RAND ROUNDS...ONCOLOGY G RAND ROUNDS Experimental Oncology Initiative Tuesday, November...
“Targeting Clonal Heterogeneity in Treatment-Refractory Glioblastoma with Novel and
Empiric Immunotherapies.”
Dr. Sheila K. Singh, PhD, MD, FRCS(C), Pediatric Neurosurgeon, McMaster Children's Hospital
Professor of Surgery, McMaster UniversityPrincipal Investigator, Stem Cell and Cancer Research Institute, McMaster University Senior Canada Research
Chair in Human Cancer Stem Cell BiologyDirector, McMaster Surgeon Scientist Program
CEO, Empirica TherapeuticsObjectives:
to understand how intro-tumoral heterogeneity at the genomic and functional levels complicates our ability tofind tractable therapeutic targets for patients with recurrent GBM
to review the application of new multi-omic profiling technology to the study of GBM modelling of recurrence, toward the definition of new therapeutic targets
to review preclinical validation required to develop therapies for GBM patients against novel biological targets
THANK YOU TO OUR SPONSORS:
REFRESHMENTS WILL BE PROVIDED BY:Department of Oncology, Schulich School of Medicine & Dentistry
London Regional Cancer Program
ONCOLOGY G RAND ROUNDS Experimental Oncology Initiative Tuesday, November 19th, 2019
12:00pm to 1:00pm in Rooms A3-924A/BLondon Regional Cancer Program
